Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375

Dow Jones

06/24

By Anvee Bhutani

Verastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations.

The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile.

Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company.

Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle.

The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca.

Verastem expects to provide another update on the program later this year.

Write to Anvee Bhutani at anvee.bhutani@wsj.com

(END) Dow Jones Newswires

June 23, 2026 16:25 ET (20:25 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2645585906"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645585906\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645585906?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-24 04:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645585906","market":"nz","top_or_hot":-1,"title":"Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Anvee Bhutani \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n</p>\n<p>\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n</p>\n<p>\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n</p>\n<p>\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n</p>\n<p>\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n</p>\n<p>\n  Verastem expects to provide another update on the program later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Verastem Reports Positive Early Data for KRAS Cancer Drug VS-7375</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVerastem Reports Positive Early Data for KRAS Cancer Drug VS-7375\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2026-06-24 04:25</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Anvee Bhutani \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/VSTM\">Verastem</a> Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n</p>\n<p>\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n</p>\n<p>\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n</p>\n<p>\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n</p>\n<p>\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n</p>\n<p>\n  Verastem expects to provide another update on the program later this year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 23, 2026 16:25 ET (20:25 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VSTM","symbol_name":"Verastem","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2645585906","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2645585906","pubTimestamp":1782246300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Verastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations.The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile.Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company.Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle.The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca.Verastem expects to provide another update on the program later this year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"VSTM":"Verastem","BK4085":"互动家庭娱乐","VS":"Versus Systems Inc.","BK4139":"生物科技"},"translate_title":"Verastem报告KRAS抗癌药物VS-7375的积极早期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VSTM":1.5,"VS":1.5},"content_text":"By Anvee Bhutani \n\n\n \n\n\nVerastem Oncology reported positive early-stage data for its experimental cancer drug VS-7375, which is being developed to treat cancers driven by KRAS G12D mutations. \n\n\n  The company said the drug showed anti-tumor activity in patients with pancreatic, colorectal and lung cancers, while maintaining a favorable safety profile. \n\n\n  Among pancreatic cancer patients receiving a higher dose of the drug, 93% saw a significant reduction in a key tumor marker, according to the company. \n\n\n  Verastem said side effects were mostly mild gastrointestinal issues, such as nausea and diarrhea, and generally improved after the first treatment cycle. \n\n\n  The company also said it plans to evaluate VS-7375 in combination with an experimental cancer treatment being developed by Erasca. \n\n\n  Verastem expects to provide another update on the program later this year. \n\n\n \n\n\n  Write to Anvee Bhutani at anvee.bhutani@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 23, 2026 16:25 ET (20:25 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}